Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Capalbo, Carlo, Scafetta, Giorgia, Filetti, Marco, Marchetti, Paolo, Bartolazzi, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/
https://www.ncbi.nlm.nih.gov/pubmed/30935099
http://dx.doi.org/10.3390/ijms20071607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/
https://www.ncbi.nlm.nih.gov/pubmed/30935099
http://dx.doi.org/10.3390/ijms20071607

Ejemplares similares